Nuvation Bio NUVB
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 23rd percentile, 5-year average -6.1x
Near the top of its 5-year range · 89th percentile, 5-year average 2.5x
#4596 of 5330 stocks by PB (1 = cheapest)
Around its usual level · 54th percentile, 5-year average 73.1x
#4261 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 6.18 | – | 2.47 | 89% (pricier than usual) | #4596 of 5330 (1 = cheapest) |
| PE | -10.23 | -10.63 | -6.12 | 23% (cheaper than usual) | – |
| PS | 6.98 | 6.51 | 73.10 | 54% (pricier than usual) | #4261 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on NUVB.
Sign in to join the discussion.